Direct answer. If someone collapses, is unresponsive and is not breathing normally, call the local emergency service, follow dispatcher instructions for CPR and use an AED if available. This is an emergency; browsing for a diagnosis or trying a supplement must not delay action.
- Gasping can be abnormal breathing; an unresponsive person needs an urgent response.
- An AED gives instructions and assesses whether a shock is indicated.
- A heart attack and cardiac arrest are different, although one can trigger the other.
- Survivors need cause assessment and an individualized prevention and recovery plan.
Table of contents
- Evidence summary
- What it is
- How it works
- The evidence-based treatments
- Supplement and lifestyle evidence
- What works and what does not
- Risks and side effects
- Important interactions
- Who needs assessment
- Clinician-led use and follow-up
- Animal and in-vitro evidence
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
| Question | Evidence role | Interpretation / confidence |
|---|---|---|
| How is it recognized? | NHLBI arrest explanation | Collapse, unresponsiveness and abnormal breathing need emergency action. |
| What does an AED do? | NHLBI AED framework | The device assesses rhythm and gives prompts; it does not imply every rhythm needs a shock. |
| What happens afterwards? | NHLBI follow-up framework | Hospital care and evaluation of the cause; no uniform device prescription or neurological prognosis. |
Confidence is high in the distinctions and assessment framework described below, supported by converging public clinical sources. This is an attributed care map, not a new comparative trial review. Confidence in a supplement replacing clinical care is insufficient in the eligible evidence assessed here. The full funding chains behind guideline drug and device trials have not been cleared.
What it is
Cardiac arrest means the heart is no longer circulating blood effectively. Consciousness and normal breathing can be lost rapidly. A dangerous rhythm is one possible cause, but not the only one. This differs from a heart attack, which injures heart muscle because its blood supply is inadequate; the two can occur in the same episode. NHLBI; heart-attack explanation.
How it works
Without effective circulation, the brain and other organs do not receive adequate oxygen. The practical response depends on recognizing the emergency and initiating the dispatcher-led sequence, rather than identifying the exact rhythm at home. An AED analyses the rhythm and prompts the user when a shock is appropriate. NHLBI.
A person who is awake with palpitations is not automatically in cardiac arrest, but associated fainting, severe breathlessness or concerning chest symptoms need urgent assessment. If consciousness and normal breathing are lost, treat the change as an emergency. NHS emergency context.
The evidence-based treatments
The immediate framework is emergency contact, CPR and an available AED used according to its prompts. Continue following the dispatcher and responders. Training is valuable, but a bystander should not delay calling while searching for the cause. NHLBI.
After circulation returns, hospital teams manage organ support and look for the cause. Selected survivors may need a defibrillator device or treatment of an underlying disease. Device choice and eligibility require specialist assessment. The source’s 2022 intensive-care details are not reproduced as a universal current temperature, oxygen or mechanical-support protocol.
Supplement and lifestyle evidence
No oral supplement is a rescue treatment for cardiac arrest. CPR and defibrillation cannot be replaced by a product marketed for circulation, electrolytes or stress. Even when an electrolyte problem contributes to a rhythm emergency, it requires clinical assessment and appropriate monitored treatment.
Recovery and prevention depend on the cause. Discuss the actual diagnosis, medicines, device instructions and activity or driving restrictions with the care team. A survivor’s plan cannot be inferred from an apparently similar story online. NHLBI follow-up context.
What works and what does not
Rapid recognition and acting on emergency instructions have immediate practical relevance. A wearable alert, a pulse oximeter reading or a supplement response is not a reason to postpone the emergency response. Having an AED nearby matters only if someone locates and uses it while the response continues.
Risks and side effects
The major immediate risk is untreated loss of circulation. Emergency measures should follow dispatcher and device prompts. An AED decides whether its shock criteria are met; users should not invent a shock schedule. NHLBI.
After survival, prognosis varies. Persistent disability, device complications and fear of recurrence deserve professional follow-up. This guide does not predict an individual person’s neurological recovery or promise that an implanted device removes all future risk.
Important interactions
A specialist should review the actual rhythm diagnosis and all prescription and nonprescription products. Drugs and supplements may influence rhythm or electrolyte balance, but a universal avoidance list would miss condition-specific risks. Do not discontinue recovery medicines because a device has been implanted or a symptom has improved.
Who needs assessment
People with a previous arrest, an inherited rhythm condition, structural heart disease or unexplained collapse need an individualized assessment. A family history may change the evaluation. This article cannot clear a reader for strenuous exercise, driving or stopping a defibrillator recommendation.
Clinician-led use and follow-up
There is no cardiac-arrest supplement regimen. Follow the emergency dispatcher, AED and responder instructions during an event. Afterwards, ask for written device and medicine guidance, a follow-up schedule, family-screening advice where appropriate and a clear plan for new symptoms.
Animal and in-vitro evidence
Cell, animal or electrolyte experiments cannot establish an oral product as a human resuscitation treatment. A mechanism relevant to electrical signalling does not prove prevention of sudden cardiac death. No such experimental result supports a supplement recommendation here.
Funding and source roles
Who paid for the evidence?
Follow named sources to the funding and relationships disclosed in this article. Numbered article disclosures preserve notes where a source is not identified. A public or university name alone does not establish independence.
View 3 more funding disclosures
This graphic reorganizes the article's disclosures; it is not a new financial audit or independence classification. Highlighted notes show different funding relationships where available. Review funding is separate from underlying trial funding. Disclosure is not proof of falsehood, and no declared conflict is not proof of complete independence.
Relevant commercial stakes include AEDs, implanted defibrillators, monitoring and emergency-care services, alongside supplements promoted for rhythm or prevention. The need to act in an emergency is separate from a later comparison of device brands, prices or sponsored trial claims.
The condition itself has no corporate owner or manufacturing country. Providers, pharmaceutical companies, device manufacturers and supplement sellers can receive revenue from different care choices. That is an incentive analysis, not an allegation of improper care. This source set is concentrated in the United States and United Kingdom. Retail manufacturing origin, batch quality and the complete financial chain of original treatment trials were not established.
Funding tier measures proximity to the subject; the credibility grade evaluates transparency and accuracy incentives. Provisional classifications are not a declaration that every conflict has been excluded. Public financial support for an educational page does not turn commercially supported underlying trials into independent efficacy evidence.
| Source | Funding / backers | Country / jurisdiction | Independence / credibility / gaps | Role in this article |
|---|---|---|---|---|
| NHLBI: cardiac arrest | US federal appropriations; NHLBI also has a permitted gift fund. Institutional funding. No page-level commercial sponsor identified; full author and underlying trial finances untraced. | United States; NIH/NHLBI, Bethesda, federal jurisdiction. | Tier 1 provisional for education; B provisional. Public accountability and review support accuracy; institutional priorities, dated content and untraced trial ties remain. | Definition and recognition |
| NHLBI: cardiac arrest treatment, May 2022 | US federal appropriations; NHLBI also has a permitted gift fund. Institutional funding. No page-level commercial sponsor identified; full author and underlying trial finances untraced. | United States; NIH/NHLBI, Bethesda, federal jurisdiction. | Tier 1 provisional for education; B provisional. Public accountability and review support accuracy; institutional priorities, dated content and untraced trial ties remain. | CPR/AED and follow-up framework; dated intensive-care detail not adopted as a current protocol |
| NHLBI: heart attack | US federal appropriations; NHLBI also has a permitted gift fund. Institutional funding. No page-level commercial sponsor identified; full author and underlying trial finances untraced. | United States; NIH/NHLBI, Bethesda, federal jurisdiction. | Tier 1 provisional for education; B provisional. Public accountability and review support accuracy; institutional priorities, dated content and untraced trial ties remain. | Distinction from infarction |
| NHS: heart attack, March 2026 | DHSC-funded NHS website; policy states no corporate sponsorship or advertising. Funding policy. Page-specific authors and complete underlying study funding unresolved. | United Kingdom; England public-information service. Local health systems differ. | Tier 1 provisional for education; B provisional. Public accountability supports accuracy; simplification, service priorities and untraced trial ties remain. | Cross-source emergency and unresponsiveness context |
| NHLBI institutional budget and funding | US federal appropriations; NHLBI also has a permitted gift fund. Institutional funding. No page-level commercial sponsor identified; full author and underlying trial finances untraced. | United States; NIH/NHLBI, Bethesda, federal jurisdiction. | Tier 3 for institutional self-disclosure; B provisional. Official financial reporting with legal accountability; selective presentation and unidentified gift donors remain possible. | Financial provenance only |
| NHS website content and funding policy | DHSC-funded NHS website; policy states no corporate sponsorship or advertising. Funding policy. Page-specific authors and complete underlying study funding unresolved. | United Kingdom; England public-information service. Local health systems differ. | Tier 3 for institutional self-disclosure; B provisional. Direct funding and editorial policy, with public accountability; actual individual declarations and implementation were not audited. | Financial and editorial self-disclosure only; policy reviewed October 2022 |
Frequently asked questions
Should I wait for the person to recover?
Unresponsiveness with abnormal breathing needs an immediate emergency call and dispatcher-led response.
Does an AED shock every collapse?
No. It assesses the rhythm and gives instructions. NHLBI.
Is every arrest caused by a heart attack?
No. The cause must be investigated. NHLBI.
Does recovery mean no further risk?
No uniform conclusion follows; specialist assessment and a prevention plan are needed.
Sources and funding notes
- NHLBI: cardiac arrest — Definition and recognition.
- NHLBI: cardiac arrest treatment, May 2022 — CPR/AED and follow-up framework; dated intensive-care detail not adopted as a current protocol.
- NHLBI: heart attack — Distinction from infarction.
- NHS: heart attack, March 2026 — Cross-source emergency and unresponsiveness context.
- NHLBI budget and legislative information — institutional public funding and gift-fund context; not a page-level donor audit.
Sources were opened and checked for the claims attributed to them. Education, financial self-disclosure and therapeutic outcome evidence are separate roles. No manufacturer-supported outcome study establishes the independent verdict in this guide. A complete systematic review, author-by-author financial audit and current local prescribing comparison were not completed. These limitations constrain the conclusion; they do not prove that clinical treatment is ineffective.
Last reviewed: October 4, 2026. Educational information; diagnosis, prescribing and emergency decisions belong with qualified professionals and local emergency services.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.
